High doses of cytosine arabinoside (HD-Ara-C) as reinforcement during remission of acute myeloid leukemia.
High doses of Cytosine-arabinoside (Ara-C) (1 to 3gm/m2 every 12 hours during 48 hours) were administered monthly to 5 acute myeloid leukemia patients during complete remissions subsequent to relapses and reinduction treatment. Plasma Ara-C was measured using a radioimmunoassay and exhibited kinetics compatible with a bi- or tri- compartimental model. Tolerance was good, with mainly gastrointestinal toxicity and somnolence. The duration of remissions was relatively long, taking into account that these were second or third remissions.
D000328:Adult; D003561:Cytarabine / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D004064:Digestive System / Q000187:drug effects; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D003561:Cytarabine